| | | | | | | | | Sponsored | | Healthcare providers face increasing pressure to make flawless clinical decisions, often with fragmented data and cognitive overload. Join Dr. Ari Frenkel, infectious disease physician and Chief Science Officer at Arkstone, on May 28 for a live webinar on how AI-powered clinical decision support is transforming the speed and quality of decision-making in infectious disease, when minutes matter most. |
|
|
| | |
| |
| | |
|
|
| | | | | | The American Cancer Society (ACS) announced revisions to their colorectal cancer screening guidelines. The organization hopes this action will lead to increased screening rates nationwide. |
|
|
|
| |
| | |
|
|
| | | | | | This article emphasizes that while performance metrics like sensitivity and specificity are crucial, laboratory adoption hinges on workflow efficiency, integration ease, and real-world operational considerations, which are often overlooked in evaluations. |
|
|
|
| |
| | |
|
|
| | | | | | Need P.A.C.E. credit? Our May CE explains that the laboratory of the future is not simply automated—it is intelligent, continuously learning from its own data and monitoring its systems, where technology strengthens rather than replaces professional judgment. |
|
|
|
| |
| | |
|
|
| | | | | | Tempus AI has launched the ArteraAI Prostate Test (mHSPC), a CLIA-certified, CAP-accredited digital pathology tool designed to personalize therapy for metastatic hormone-sensitive prostate cancer patients, addressing a key treatment gap. |
|
|
| | Artera has been granted U.S. Food and Drug Administration (FDA) clearance of ArteraAI Breast for use in patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer, according to an announcement. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
